India, July 17 -- Zydus Lifesciences Ltd. has announced the successful completion of a Remote Regulatory Assessment (RRA) by the USFDA at its formulations manufacturing facility in Matoda, Gujarat. The assessment was conducted in connection with the Prior Approval Supplement (PAS) for Atorvastatin Calcium Tablets USP in 10 mg, 20 mg, 40 mg, and 80 mg strengths.
At the conclusion of the assessment, no observations were issued, and the facility has been recommended for approval.
This disclosure is being made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....